Mr. Coleridge has served as the CEO of Humanzyme, Inc for the past 5 years. A highly experienced life science/medical technology executive, Mr. Coleridge worked at Millipore as Biotechnology Market Manager before entering the world of early stage companies. He served as CEO of Synthon Chiragenics (sold to Avecia), was Co-Founder of Apple Medical (sold to Cooper Surgical), and Executive Vice President of FEI Women’s Health (sold to Barr Laboratories/Teva Pharmaceuticals), developer of the only non-hormonal female contraceptive. Mr. Coleridge has spent more than 20 years starting or being part of the senior management team of several early-stage life science companies, including Kingston Diagnostics, developer of the first whole blood cholesterol test (Licensed to Warner Lambert/Pfizer). After the sale of FEI to Barr Laboratories in 2005, Mr. Coleridge joined Morningside Technology Advisory, LLC. He is also a member of the Board of Directors of Excera Orthopedics and Vioptix, Inc.

Mark Azam, Ph.D., VP of R&D and Manufacturing

Mark has spent 16 years in biopharmaceutical and biotechnology field. Prior to joining HumanZyme, Mark has held management and director positions with several companies including Life Technologies (ThermoFisher) and ChanTest (Charles River). He has been in Cell Line Engineering, Bioprocess and Protein Production space for 20+ years. During the last 12 years developed protein production processes compliant with ISO9001, USDA and cGMP (21CFR part 210 and 211).